TY - JOUR
T1 - Opioid formulations with sequestered naltrexone
T2 - A perspective review
AU - Taylor, Robert
AU - Raffa, Robert B.
AU - Pergolizzi, Joseph V.
PY - 2014
Y1 - 2014
N2 - In response to good-intentioned efforts to correct the traditional undertreatment of pain, opioid prescribing experienced a dramatic increase over the past decade. But there is now concern that the pendulum has swung too far in the opposite direction, with a rise in morbidity and mortality associated with prescription opioid misuse and abuse. Yet despite potential problems, opioids are a mainstay for the treatment of pain and are an important component of a comprehensive pain management strategy. Therefore, the overall goal of pain management is to decrease pain and to improve patient functioning and quality of life, while monitoring for adverse effects or aberrant behaviors. That is, to balance effective chronic pain management with appropriate use of opioids. Toward this end, several abuse deterrent strategies (formulations) have been, and continue to be, developed. Several major ones are reviewed here. These products should be a first step in trying to address diversion and abuse in a manner that does not discriminate against any particular patient and aligns with universal prescribing precautions. They should also comprise only one aspect of an overall opioid risk management plan.
AB - In response to good-intentioned efforts to correct the traditional undertreatment of pain, opioid prescribing experienced a dramatic increase over the past decade. But there is now concern that the pendulum has swung too far in the opposite direction, with a rise in morbidity and mortality associated with prescription opioid misuse and abuse. Yet despite potential problems, opioids are a mainstay for the treatment of pain and are an important component of a comprehensive pain management strategy. Therefore, the overall goal of pain management is to decrease pain and to improve patient functioning and quality of life, while monitoring for adverse effects or aberrant behaviors. That is, to balance effective chronic pain management with appropriate use of opioids. Toward this end, several abuse deterrent strategies (formulations) have been, and continue to be, developed. Several major ones are reviewed here. These products should be a first step in trying to address diversion and abuse in a manner that does not discriminate against any particular patient and aligns with universal prescribing precautions. They should also comprise only one aspect of an overall opioid risk management plan.
KW - abuse deterrent
KW - analgesic
KW - chronic pain
KW - opioid
KW - opioid risk management
UR - http://www.scopus.com/inward/record.url?scp=84899974613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899974613&partnerID=8YFLogxK
U2 - 10.1177/2042098614526769
DO - 10.1177/2042098614526769
M3 - Article
C2 - 25083268
AN - SCOPUS:84899974613
SN - 2042-0986
VL - 5
SP - 129
EP - 137
JO - Therapeutic Advances in Drug Safety
JF - Therapeutic Advances in Drug Safety
IS - 3
ER -